Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec 21;3(114):114rv3.
doi: 10.1126/scitranslmed.3003149.

Forty-year journey of angiogenesis translational research

Affiliations
Review

Forty-year journey of angiogenesis translational research

Yihai Cao et al. Sci Transl Med. .

Abstract

Forty years ago, Judah Folkman predicted that tumor growth is dependent on angiogenesis and that inhibiting this process might be a new strategy for cancer therapy. This hypothesis formed the foundation of a new field of research that represents an excellent example of how a groundbreaking scientific discovery can be translated to yield benefits for patients. Today, antiangiogenic drugs are used to treat human cancers and retinal vascular diseases. Here, we guide readers through 40 years of angiogenesis research and discuss challenges of antiangiogenic therapy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Y.C. has equity interest in ClanoTech Company, which develops antiangiogenic drugs. R.K. is a paid consultant for Taiho Pharmaceuticals, GlaxoSmithKline, and MolMed, and receives honoraria from Roche, Adnexus/BMS, AVEO, Acceleron, and Amgen. R.L. has founded, consults for, and is a member of the board of a variety of life sciences companies.

Figures

Fig. 1.
Fig. 1.. Not like the other.
Shown are possible bases for differences in response to ADs between preclinical animal models and human patients. S.C., subcutaneous.
Fig. 2.
Fig. 2.. Constellation of challenges.
Many unanswered questions remain in the realm of antiangiogenic cancer therapy. ECs, endothelial cells; CECs, circulating endothelial cells; CEPCs, circulating endothelial progenitor cells; AF, angiogenic factor; GI, gastrointestinal.

References

    1. Folkman J, Merler E, Abernathy C, Williams G, Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med 133, 275–288 (1971). - PMC - PubMed
    1. Folkman J, Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med 285, 1182–1186 (1971). - PubMed
    1. Ferrara N, Hillan KJ, Gerber HP, Novotny W, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov 3, 391–400 (2004). - PubMed
    1. Folkman J, Haudenschild CC, Zetter BR, Long-term culture of capillary endothelial cells. Proc. Natl. Acad. Sci. U.S.A 76, 5217–5221 (1979). - PMC - PubMed
    1. Langer R, Brem H, Falterman K, Klein M, Folkman J, Isolations of a cartilage factor that inhibits tumor neovascularization. Science 193, 70–72 (1976). - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources